Endothelial dysfunction in morbid obesity

Current Pharmaceutical Design

Volumn 19, Issue 32, 2013, Pages 5718-5729

  Mauricio, Maria Dolores ^a,b   Aldasoro, Martin ^a,b   Ortega, Joaquin ^a,b   Vila, José María ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Bariatric surgery (BS); Endothelial dysfunction; Inflammation; Morbid obesity; Nitric oxide (NO); Oxidative stress

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; INTERLEUKIN 18; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

AORTA; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; COMORBIDITY; DIASTOLIC DYSFUNCTION; DIET THERAPY; ENDOTHELIAL DYSFUNCTION; EXERCISE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORBID OBESITY; MORTALITY; MUSCLE RIGIDITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SLEEP DISORDERED BREATHING; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; NITRIC OXIDE; OBESITY, MORBID; OXIDATIVE STRESS; VASODILATION; WEIGHT LOSS;

EID: 84883542294     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319320007     Document Type: Review

References (237)

1. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-253.
2. Diet, nutrition and the prevention of chronic diseases. World Health Organ Tech Rep Ser 2003; 916: i-149, backcover.
3. Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med 2012; 42(6): 563-70.
4. Williams IL, Wheatcroft SB, Shah AM, et al. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes Relat Metab Disord 2002; 26(6): 754-64.
5. Bakker W, Eringa EC, Sipkema P, et al. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res 2009; 335(1): 165-89.
6. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365(9468): 1415-28.
7. Catenacci VA, Hill JO, Wyatt HR. The obesity epidemic. Clin Chest Med 2009; 30(3): 415-44, vii.
8. Hu G, Tuomilehto J, Silventoinen K, et al. The effects of physical activity and body mass index on cardiovascular, cancer and allcause mortality among 47 212 middle-aged Finnish men and women. Int J Obes (Lond) 2005; 29(8): 894-902.
9. Key TJ, Schatzkin A, Willett WC, et al. Diet, nutrition and the prevention of cancer. Public Health Nutr 2004; 7(1A): 187-200.
10. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998; 105(1A): 32S-9S.
11. Moncada S, Herman AG, Higgs EA, et al. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res 1977; 11(3): 323-44.
12. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288(5789): 373-6.
13. Ignarro LJ, Byrns RE, Buga GM, et al. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987; 61(6): 866-79.
14. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327(6122): 524-6.
15. Sugerman H, Windsor A, Bessos M, et al. Intra-abdominal pressure, sagittal abdominal diameter and obesity comorbidity. J Intern Med 1997; 241(1): 71-9.
16. Harman PK, Kron IL, McLachlan HD, et al. Elevated intraabdominal pressure and renal function. Ann Surg 1982; 196(5): 594-7.
17. Hackney JD, Crane MG, Collier CC, et al. Syndrome of extreme obesity and hypoventilation: studies of etiology. Ann Intern Med 1959; 51: 541-52.
18. Doty JM, Saggi BH, Sugerman HJ, et al. Effect of increased renal venous pressure on renal function. J Trauma 1999; 47(6): 1000-3.
19. Aud-din A, Meterissian S, Lisbona R, et al. Assessment of cardiac function in patients who were morbidly obese. Surgery 1990; 108(4): 809-818.
20. Hall JE, Crook ED, Jones DW, et al. Mechanisms of obesityassociated cardiovascular and renal disease. Am J Med Sci 2002; 324(3): 127-37.
21. El-Atat F, Aneja A, Mcfarlane S, et al. Obesity and hypertension. Endocrinol Metab Clin North Am 2003; 32(4): 823-54.
22. Sugerman HJ, Fairman RP, Baron PL, et al. Gastric surgery for respiratory insufficiency of obesity. Chest 1986; 90(1): 81-6.
23. Guilleminault C, Motta J, Mihm F, et al. Obstructive sleep apnea and cardiac index. Chest 1986; 89(3): 331-4.
24. Young T, Palta M, Dempsey J, et al. The occurrence of sleepdisordered breathing among middle-aged adults. N Engl J Med 1993; 328(17): 1230-5.
25. Young T, Shahar E, Nieto FJ, et al. Predictors of sleep-disordered breathing in community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med 2002; 162(8): 893-900.
26. Sugerman HJ. The pathophysiology of severe obesity and the effects of surgically induced weight loss. Surg Obes Relat Dis 2005; 1(2): 109-19.
27. Bady E, Achkar A, Pascal S, et al. Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax 2000; 55(11): 934-9.
28. Ridings PC, Bloomfield GL, Blocher CR, et al. Cardiopulmonary effects of raised intra-abdominal pressure before and after intravascular volume expansion. J Trauma 1995; 39(6): 1071-5.
29. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001; 321(4): 225-36.
30. Sutton-Tyrrell K, Newman A, Simonsick EM, et al. Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. Hypertension 2001; 38(3): 429-33.
31. Messerli FH, Sundgaard-Riise K, Reisin E, et al. Disparate cardiovascular effects of obesity and arterial hypertension. Am J Med 1983; 74(5): 808-12.
32. Alpert MA, Terry BE, Kelly DL. Effect of weight loss on cardiac chamber size, wall thickness and left ventricular function in morbid obesity. Am J Cardiol 1985; 55(6): 783-6.
33. Garavaglia GE, Messerli FH, Nunez BD, et al. Myocardial contractility and left ventricular function in obese patients with essential hypertension. Am J Cardiol 1988; 62(9): 594-7.
34. Levy D, Anderson KM, Savage DD, et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108(1): 7-13.
35. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355(3): 260-9.
36. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67(5): 968-77.
37. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322(13): 882-9.
38. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): 405-12.
39. Stapleton PA, James ME, Goodwill AG, et al. Obesity and vascular dysfunction. Pathophysiology 2008; 15(2): 79-89.
40. Busetto L, Sbraccia P, Frittitta L, et al. The growing role of bariatric surgery in the management of type 2 diabetes: evidences and open questions. Obes Surg 2011; 21(9): 1451-7.
41. Kopp HP, Kopp CW, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23(6): 1042-7.
42. Clements RH, Gonzalez QH, Long CI, et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg 2004; 70(1): 1-4.
43. Schernthaner GH, Kopp HP, Kriwanek S, et al. Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte-chemoattractant-protein-1 in morbid obesity. Obes Surg 2006; 16(6): 709-15.
44. Ruano M, Silvestre V, Castro R, et al. Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis. Obes Surg 2005; 15(5): 670-6.
45. Miller GD, Nicklas BJ, Fernandez A. Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis 2011; 7(5): 618-24.
46. Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm 2010; 2010: 802078.
47. Haller H. Endothelial function. General considerations. Drugs 1997; 53 Suppl 1: 1-10.
48. Sandoo A, van Zanten JJ, Metsios GS, et al. The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J 2010; 4: 302-12.
49. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329(27): 2002-12.
50. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323(1): 27-36.
51. Schiffrin EL. A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol 2001; 38 Suppl 2: S3-S6.
52. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99(24): 3092-5.
53. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006; 291(3): H985-1002.
54. Davel AP, Wenceslau CF, Akamine EH, et al. Endothelial dysfunction in cardiovascular and endocrine-metabolic diseases: an update. Braz J Med Biol Res 2011; 44(9): 920-32.
55. Okubo K, Hayashi K, Wakino S, et al. Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. Hypertens Res 2005; 28(2): 181-9.
56. Giles TD, Sander GE, Nossaman BD, et al. Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins. J Clin Hypertens (Greenwich) 2012; 14(4): 198-205.
57. Sivitz WI, Wayson SM, Bayless ML, et al. Obesity impairs vascular relaxation in human subjects: hyperglycemia exaggerates adrenergic vasoconstriction arterial dysfunction in obesity and diabetes. J Diabetes Complications 2007; 21(3): 149-57.
58. Et-Taouil K, Safar M, Plante GE. Mechanisms and consequences of large artery rigidity. Can J Physiol Pharmacol 2003; 81(3): 205-11.
59. Goodfellow J, Ramsey MW, Luddington LA, et al. Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin dependent diabetes. BMJ 1996; 312(7033): 744-5.
60. Hogikyan RV, Galecki AT, Pitt B, et al. Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes independent of obesity. J Clin Endocrinol Metab 1998; 83(6): 1946-52.
61. Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97(11): 2601-10.
62. Perticone F, Ceravolo R, Candigliota M, et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 2001; 50(1): 159-65.
63. Traupe T, D'Uscio LV, Muenter K, et al. Effects of obesity on endothelium-dependent reactivity during acute nitric oxide synthase inhibition: modulatory role of endothelin. Clin Sci (Lond) 2002; 103 Suppl 48: 13S-5S.
64. de Jongh RT, Serne EH, IJzerman RG, et al. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 2004; 109(21): 2529-35.
65. de Jongh RT, Serne EH, IJzerman RG, et al. Impaired local microvascular vasodilatory effects of insulin and reduced skin microvascular vasomotion in obese women. Microvasc Res 2008; 75(2): 256-62.
66. Nascimento TB, Baptista RF, Pereira PC, et al. Vascular alterations in high-fat diet-obese rats: role of endothelial L-arginine/NO pathway. Arq Bras Cardiol 2011; 97(1): 40-5.
67. Jerez S, Scacchi F, Sierra L, et al. Vascular hyporeactivity to angiotensin II and noradrenaline in a rabbit model of obesity. J Cardiovasc Pharmacol 2012; 59(1): 49-57.
68. De CC, Porteri E, Rizzoni D, et al. Effects of weight loss on structural and functional alterations of subcutaneous small arteries in obese patients. Hypertension 2011; 58(1): 29-36.
69. Grassi G, Seravalle G, Scopelliti F, et al. Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity. Obesity (Silver Spring) 2010; 18(1): 92-8.
70. Rizzoni D, Porteri E, Guelfi D, et al. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 2001; 103(9): 1238-44.
71. Rizzoni D, Porteri E, Giustina A, et al. Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries. Hypertension 2004; 43(3): 561-5.
72. Schofield I, Malik R, Izzard A, et al. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002; 106(24): 3037-43.
73. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002; 10 Suppl 2: 97S-104S.
74. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003; 11(11): 1278-89.
75. Lau DC, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005; 288(5): H2031-41.
76. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115(5): 911-9.
77. Yamagishi S, Nakamura K, Jinnouchi Y, et al. Molecular mechanisms for vascular injury in the metabolic syndrome. Drugs Exp Clin Res 2005; 31(3): 123-29.
78. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340(2): 115-26.
79. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010; 17(4): 332-41.
80. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 2008; 103(5): 398-406.
81. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2(8567): 1057-8.
82. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83(5): 1774-77.
83. Palmer RM, Rees DD, Ashton DS, et al. L-arginine is the physiological precursor for the formation of nitric oxide in endotheliumdependent relaxation. Biochem Biophys Res Commun 1988; 153(3): 1251-6.
84. Veelken R, Hilgers KF, Hartner A, et al. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol 2000; 11(1): 71-9.
85. Etienne P, Pares-Herbute N, Monnier L. Enhanced antiproliferative effect of nitric oxide in cultured smooth muscle cells from diabetic rats. J Cardiovasc Pharmacol 1996; 27(1): 140-6.
86. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24(6): 998-1005.
87. Waldman SA, Murad F. Biochemical mechanisms underlying vascular smooth muscle relaxation: the guanylate cyclase-cyclic GMP system. J Cardiovasc Pharmacol 1988; 12 Suppl 5: S115-8.
88. Landim MB, Casella FA, Chagas AC. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics (Sao Paulo) 2009; 64(5): 471-8.
89. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87(10): 840-4.
90. Laine H, Yki-Jarvinen H, Kirvela O, et al. Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. J Clin Invest 1998; 101(5): 1156-62.
91. Van Guilder GP, Stauffer BL, Greiner JJ, et al. Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists. Am J Physiol Heart Circ Physiol 2008; 294(4): H1685-92.
92. Arcaro G, Zamboni M, Rossi L, et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes Relat Metab Disord 1999; 23(9): 936-42.
93. Kobayasi R, Akamine EH, Davel AP, et al. Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet-induced obesity in mice. J Hypertens 2010; 28(10): 2111-9.
94. Sansbury BE, Cummins TD, Tang Y, et al. Overexpression of endothelial nitric oxide synthase prevents diet-induced obesity and regulates adipocyte phenotype. Circ Res 2012; 111(9): 1176-89.
95. Montagnani M, Chen H, Barr VA, et al. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem 2001; 276(32): 30392-8.
96. Anderson EA, Hoffman RP, Balon TW, et al. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991; 87(6): 2246-52.
97. Tack CJ, Schefman AE, Willems JL, et al. Direct vasodilator effects of physiological hyperinsulin-aemia in human skeletal muscle. Eur J Clin Invest 1996; 26(9): 772-8.
98. Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002; 105(5): 576-82.
99. Feldman RD, Bierbrier GS. Insulin-mediated vasodilation: impairment with increased blood pressure and body mass. Lancet 1993; 342(8873): 707-9.
100. Kim JA, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113(15): 1888-904.
101. Clerk LH, Vincent MA, Jahn LA, et al. Obesity blunts insulinmediated microvascular recruitment in human forearm muscle. Diabetes 2006; 55(5): 1436-42.
102. Reyes-Soffer G, Holleran S, Di Tullio MR, et al. Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. Metabolism 2010; 59(9): 1365-71.
103. Fernandez-Sanchez A, Madrigal-Santillan E, Bautista M, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci 2011; 12(5): 3117-32.
104. Sikaris KA. The clinical biochemistry of obesity. Clin Biochem Rev 2004; 25(3): 165-81.
105. Vazzana N, Guagnano MT, Cuccurullo C, et al. Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress. J Clin Endocrinol Metab 2012; 97(9): E1726-30.
106. Davi G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288(16): 2008-14.
107. Fonseca-Alaniz MH, Takada J, onso-Vale MI, et al. Adipose tissue as an endocrine organ: from theory to practice. J Pediatr (Rio J) 2007; 83(5 Suppl): S192-S203.
108. Alikasifoglu A, Gonc N, Ozon ZA, et al. The relationship between serum adiponectin, tumor necrosis factor-alpha, leptin levels and insulin sensitivity in childhood and adolescent obesity: adiponectin is a marker of metabolic syndrome. J Clin Res Pediatr Endocrinol 2009; 1(5): 233-9.
109. Gueugnon C, Mougin F, Simon-Rigaud ML, et al. Effects of an inpatient treatment program based on regular exercise and a balanced diet on high molecular weight adiponectin, resistin levels, and insulin resistance in adolescents with severe obesity. Appl Physiol Nutr Metab 2012; 37(4): 672-9.
110. Li S, Shin HJ, Ding EL, et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302(2): 179-88.
111. Sturm W, Sandhofer A, Engl J, et al. Influence of visceral obesity and liver fat on vascular structure and function in obese subjects. Obesity (Silver Spring) 2009; 17(9): 1783-8.
112. Lin LY, Lee WJ, Shen HN, et al. Nitric oxide production is paradoxically decreased after weight reduction surgery in morbid obesity patients. Atherosclerosis 2007; 190(2): 436-42.
113. Vecchione C, Maffei A, Colella S, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002; 51(1): 168-73.
114. Luscher TF, Tanner FC. Endothelial regulation of vascular tone and growth. Am J Hypertens 1993; 6(7 Pt 2): 283S-93S.
115. Sainz JM, Reche C, Rabano MA, et al. Effects of nitric oxide on aldosterone synthesis and nitric oxide synthase activity in glomerulosa cells from bovine adrenal gland. Endocrine 2004; 24(1): 61-71.
116. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339(8793): 572-5.
117. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43(3): 542-8.
118. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24(6): 1023-30.
119. Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme, NG, NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989; 264(17): 10205-9.
120. Leiper JM, Santa MJ, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343 Pt 1: 209-14.
121. Tanaka M, Sydow K, Gunawan F, et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005; 112(11): 1549-56.
122. Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007; 13(2): 198-203.
123. MacAllister RJ, Whitley GS, Vallance P. Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 1994; 45(3): 737-42.
124. Segarra G, Medina P, Ballester RM, et al. Effects of some guanidino compounds on human cerebral arteries. Stroke 1999; 30(10): 2206-10.
125. Krzyzanowska K, Mittermayer F, Kopp HP, et al. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol Metab 2004; 89(12): 6277-81.
126. Siervo M, Bluck LJ. In vivo nitric oxide synthesis, insulin sensitivity, and asymmetric dimethylarginine in obese subjects without and with metabolic syndrome. Metabolism 2012; 61(5): 680-8.
127. Boger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87(2): 99-105.
128. MacAllister RJ, Parry H, Kimoto M, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119(8): 1533-40.
129. Fogarty RD, Abhary S, Javadiyan S, et al. Relationship between DDAH gene variants and serum ADMA level in individuals with type 1 diabetes. J Diabetes Complications 2012; 26(3): 195-8.
130. Miyamoto T, Ogino N, Yamamoto S, et al. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 1976; 251(9): 2629-36.
131. Catella-Lawson F. Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. Neurology 2001; 57(5 Suppl 2): S5-S7.
132. Caughey GE, Cleland LG, Penglis PS, et al. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001; 167(5): 2831-8.
133. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96(1): 272-7.
134. Gollasch M, Ried C, Bychkov R, et al. K+ currents in human coronary artery vascular smooth muscle cells. Circ Res 1996; 78(4): 676-88.
135. Corriu C, Feletou M, Edwards G, et al. Differential effects of prostacyclin and iloprost in the isolated carotid artery of the guineapig. Eur J Pharmacol 2001; 426(1-2): 89-94.
136. Yuhki K, Kashiwagi H, Kojima F, et al. Roles of prostanoids in the pathogenesis of cardiovascular diseases. Int Angiol 2010; 29(2 Suppl): 19-27.
137. Iniguez MA, Cacheiro-Llaguno C, Cuesta N, et al. Prostanoid function and cardiovascular disease. Arch Physiol Biochem 2008; 114(3): 201-9.
138. Traupe T, Lang M, Goettsch W, et al. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 2002; 20(11): 2239-45.
139. Mendizabal Y, Llorens S, Nava E. Reactivity of the aorta and mesenteric resistance arteries from the obese spontaneously hypertensive rat: effects of glitazones. Am J Physiol Heart Circ Physiol 2011; 301(4): H1319-30.
140. Garcia-Redondo AB, Briones AM, Beltran AE, et al. Hypertension increases contractile responses to hydrogen peroxide in resistance arteries through increased thromboxane A2, Ca2+, and superoxide anion levels. J Pharmacol Exp Ther 2009; 328(1): 19-27.
141. Xiang L, Dearman J, Abram SR, et al. Insulin resistance and impaired functional vasodilation in obese Zucker rats. Am J Physiol Heart Circ Physiol 2008; 294(4): H1658-66.
142. Hodnett BL, Dearman JA, Carter CB, et al. Attenuated PGI2 synthesis in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2009; 296(3): R715-21.
143. Du X, Edelstein D, Obici S, et al. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006; 116(4): 1071-80.
144. Jackson WF, Konig A, Dambacher T, et al. Prostacyclin-induced vasodilation in rabbit heart is mediated by ATP-sensitive potassium channels. Am J Physiol 1993; 264(1 Pt 2): H238-43.
145. Schubert R, Serebryakov VN, Mewes H, et al. Iloprost dilates rat small arteries: role of K(ATP)-and K(Ca)-channel activation by cAMP-dependent protein kinase. Am J Physiol 1997; 272(3 Pt 2): H1147-56.
146. Xiang L, Naik JS, Hodnett BL, et al. Altered arachidonic acid metabolism impairs functional vasodilation in metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 2006; 290(1): R134-8.
147. Frisbee JC. Impaired skeletal muscle perfusion in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2003; 285(5): R1124-34.
148. Lobato NS, Filgueira FP, Hagihara GN, et al. Improvement of metabolic parameters and vascular function by metformin in obese non-diabetic rats. Life Sci 2012; 90(5-6): 228-35.
149. Sato N, Kaneko M, Tamura M, et al. The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. Diabetes 2010; 59(4): 1092-1100.
150. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995; 92(11): 3337-49.
151. Shimokawa H, Yasutake H, Fujii K, et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 1996; 28(5): 703-11.
152. Andersson DA, Zygmunt PM, Movahed P, et al. Effects of inhibitors of small-and intermediate-conductance calcium-activated potassium channels, inwardly-rectifying potassium channels and Na(+)/K(+) ATPase on EDHF relaxations in the rat hepatic artery. Br J Pharmacol 2000; 129(7): 1490-6.
153. Corriu C, Feletou M, Canet E, et al. Endothelium-derived factors and hyperpolarization of the carotid artery of the guinea-pig. Br J Pharmacol 1996; 119(5): 959-64.
154. Dora KA, Gallagher NT, McNeish A, et al. Modulation of endothelial cell KCa3.1 channels during endothelium-derived hyperpolarizing factor signaling in mesenteric resistance arteries. Circ Res 2008; 102(10): 1247-55.
155. Martinez-Leon JB, Segarra G, Medina P, et al. Ca2+-activated K+ channels mediate relaxation of forearm veins in chronic renal failure. J Hypertens 2003; 21(10): 1927-34.
156. Mauricio MD, Serna E, Cortina B, et al. Role of Ca2+-activated K+ channels on adrenergic responses of human saphenous vein. Am J Hypertens 2007; 20(1): 78-82.
157. Bychkov R, Burnham MP, Richards GR, et al. Characterization of a charybdotoxin-sensitive intermediate conductance Ca2+-activated K+ channel in porcine coronary endothelium: relevance to EDHF. Br J Pharmacol 2002; 137(8): 1346-54.
158. Grgic I, Kaistha BP, Hoyer J, et al. Endothelial Ca+-activated K+ channels in normal and impaired EDHF-dilator responses--relevance to cardiovascular pathologies and drug discovery. Br J Pharmacol 2009; 157(4): 509-26.
159. Xu Y, Henning RH, van der Want JJ, et al. Disruption of endothelial caveolae is associated with impairment of both NO-as well as EDHF in acetylcholine-induced relaxation depending on their relative contribution in different vascular beds. Life Sci 2007; 80(18): 1678-85.
160. Feletou M, Vanhoutte PM. EDHF: new therapeutic targets? Pharmacol Res 2004; 49(6): 565-80.
161. McLean PG, Aston D, Sarkar D, et al. Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers. Circ Res 2002; 90(4): 465-72.
162. Malmsjo M, Bergdahl A, Zhao XH, et al. Enhanced acetylcholine and P2Y-receptor stimulated vascular EDHF-dilatation in congestive heart failure. Cardiovasc Res 1999; 43(1): 200-9.
163. Sofola OA, Knill A, Hainsworth R, et al. Change in endothelial function in mesenteric arteries of Sprague-Dawley rats fed a high salt diet. J Physiol 2002; 543(Pt 1): 255-60.
164. Katz SD, Krum H. Acetylcholine-mediated vasodilation in the forearm circulation of patients with heart failure: indirect evidence for the role of endothelium-derived hyperpolarizing factor. Am J Cardiol 2001; 87(9): 1089-92.
165. Bauersachs J, Popp R, Hecker M, et al. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 1996; 94(12): 3341-7.
166. Ellis A, Cheng ZJ, Li Y, et al. Effects of a Western diet versus high glucose on endothelium-dependent relaxation in murine micro-and macro-vasculature. Eur J Pharmacol 2008; 601(1-3): 111-7.
167. Feher A, Rutkai I, Beleznai T, et al. Caveolin-1 limits the contribution of BK(Ca) channel to EDHF-mediated arteriolar dilation: implications in diet-induced obesity. Cardiovasc Res 2010; 87(4): 732-9.
168. Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Role of nitric oxide and endothelium-derived hyperpolarizing factor (EDHF) in the regulation of blood pressure by leptin in lean and obese rats. Life Sci 2006; 79(1): 63-71.
169. Gao YJ, Lu C, Su LY, et al. Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide. Br J Pharmacol 2007; 151(3): 323-31.
170. Gao YJ, Zeng ZH, Teoh K, et al. Perivascular adipose tissue modulates vascular function in the human internal thoracic artery. J Thorac Cardiovasc Surg 2005; 130(4): 1130-6.
171. Vigili de KS, Kiwanuka E, Tiengo A, et al. Visceral obesity is characterized by impaired nitric oxide-independent vasodilation. Eur Heart J 2003; 24(13): 1210-5.
172. Dawes M, Sieniawska C, Delves T, et al. Barium reduces resting blood flow and inhibits potassium-induced vasodilation in the human forearm. Circulation 2002; 105(11): 1323-8.
173. Edwards G, Dora KA, Gardener MJ, et al. K+ is an endotheliumderived hyperpolarizing factor in rat arteries. Nature 1998; 396(6708): 269-72.
174. Young EJ, Hill MA, Wiehler WB, et al. Reduced EDHF responses and connexin activity in mesenteric arteries from the insulinresistant obese Zucker rat. Diabetologia 2008; 51(5): 872-81.
175. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332(6163): 411-5.
176. Vila JM, Martin de AE, Martinez MC, et al. Endothelin action on goat cerebral arteries. J Pharm Pharmacol 1990; 42(5): 370-2.
177. Arai H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348(6303): 730-732.
178. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995; 92(3): 357-63.
179. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97(8): 752-6.
180. Yang ZH, Richard V, von SL, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation 1990; 82(1): 188-95.
181. Henrion D, Laher I. Potentiation of norepinephrine-induced contractions by endothelin-1 in the rabbit aorta. Hypertension 1993; 22(1): 78-83.
182. Kita S, Taguchi Y, Chatani S, et al. Effects of endothelin-1 on norepinephrine-induced vasoconstriction in deoxycorticosterone acetate-salt hypertensive rats. Eur J Pharmacol 1998; 344(1): 53-7.
183. Vila JM, Medina P, Segarra G, et al. Endothelin-1-induced potentiation of adrenergic responses in the rabbit pulmonary artery: role of thromboxane A(2). Eur J Pharmacol 2001; 413(2-3): 247-54.
184. Weil BR, Westby CM, Van Guilder GP, et al. Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol 2011; 301(3): H689-95.
185. Parrinello G, Scaglione R, Pinto A, et al. Central obesity and hypertension: the role of plasma endothelin. Am J Hypertens 1996; 9(12 Pt 1): 1186-91.
186. Tiret L, Poirier O, Hallet V, et al. The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 1999; 33(5): 1169-74.
187. Barton M, Carmona R, Morawietz H, et al. Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension 2000; 35(1 Pt 2): 329-36.
188. Liu JL, Pliquett RU, Brewer E, et al. Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure. Am J Physiol Regul Integr Comp Physiol 2001; 280(6): R1906-13.
189. Barton M, Carmona R, Ortmann J, et al. Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol 2003; 35(6): 826-37.
190. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 2004; 142(2): 231-55.
191. Kurowska EM. Nitric oxide therapies in vascular diseases. Curr Pharm Des 2002; 8(3): 155-66.
192. Farb MG, Ganley-Leal L, Mott M, et al. Arteriolar function in visceral adipose tissue is impaired in human obesity. Arterioscler Thromb Vasc Biol 2012; 32(2): 467-73.
193. Uzun H, Zengin K, Taskin M, et al. Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable gastric banding. Obes Surg 2004; 14(5): 659-65.
194. Garcia-Fuentes E, Murri M, Garrido-Sanchez L, et al. PPARgamma expression after a high-fat meal is associated with plasma superoxide dismutase activity in morbidly obese persons. Obesity (Silver Spring) 2010; 18(5): 952-8.
195. Vincent HK, Innes KE, Vincent KR. Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Diabetes Obes Metab 2007; 9(6): 813-39.
196. Lee YS, Kim AY, Choi JW, et al. Dysregulation of adipose glutathione peroxidase 3 in obesity contributes to local and systemic oxidative stress. Mol Endocrinol 2008; 22(9): 2176-89.
197. Aasheim ET, Hofso D, Hjelmesaeth J, et al. Vitamin status in morbidly obese patients: a cross-sectional study. Am J Clin Nutr 2008; 87(2): 362-9.
198. Higdon JV, Frei B. Obesity and oxidative stress: a direct link to CVD? Arterioscler Thromb Vasc Biol 2003; 23(3): 365-7.
199. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334(18): 1145-9.
200. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293(11): 1338-47.
201. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 154-60.
202. Suzuki K, Inoue T, Hioki R, et al. Association of abdominal obesity with decreased serum levels of carotenoids in a healthy Japanese population. Clin Nutr 2006; 25(5): 780-9.
203. Lavrovsky Y, Chatterjee B, Clark RA, et al. Role of redoxregulated transcription factors in inflammation, aging and agerelated diseases. Exp Gerontol 2000; 35(5): 521-32.
204. Anderson JW, Grant L, Gotthelf L, et al. Weight loss and longterm follow-up of severely obese individuals treated with an intense behavioral program. Int J Obes (Lond) 2007; 31(3): 488-93.
205. Nguyen T, Lau DC. The obesity epidemic and its impact on hypertension. Can J Cardiol 2012; 28(3): 326-33.
206. O'Brien PE, Dixon JB, Laurie C, et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 2006; 144(9): 625-33.
207. Dixon JB, Schachter LM, O'Brien PE, et al. Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial. JAMA 2012; 308(11): 1142-9.
208. Schernthaner G, Morton JM. Bariatric surgery in patients with morbid obesity and type 2 diabetes. Diabetes Care 2008; 31 Suppl 2: S297-302.
209. Greve JW. Surgical treatment of morbid obesity: role of the gastroenterologist. Scand J Gastroenterol Suppl 2000; (232): 60-4.
210. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351(26): 2683-93.
211. Schernthaner G, Brix JM, Kopp HP, et al. Cure of type 2 diabetes by metabolic surgery? A critical analysis of the evidence in 2010. Diabetes Care 2011; 34 Suppl 2: S355-60.
212. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357(8): 753-61.
213. Rosa G, Mingrone G, Manco M, et al. Molecular mechanisms of diabetes reversibility after bariatric surgery. Int J Obes (Lond) 2007; 31(9): 1429-36.
214. Christou NV, Look D, MacLean LD. Weight gain after short-and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg 2006; 244(5): 734-40.
215. Johnson RJ, Johnson BL, Blackhurst DW, et al. Bariatric surgery is associated with a reduced risk of mortality in morbidly obese patients with a history of major cardiovascular events. Am Surg 2012; 78(6): 685-92.
216. Nordstrand N, Hertel JK, Hofso D, et al. A controlled clinical trial of the effect of gastric bypass surgery and intensive lifestyle intervention on nocturnal hypertension and the circadian blood pressure rhythm in patients with morbid obesity. Surgery 2012; 151(5): 674-80.
217. Brethauer SA, Heneghan HM, Eldar S, et al. Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients. Surg Endosc 2011; 25(8): 2650-9.
218. Dall'Asta C, Vedani P, Manunta P, et al. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovasc Dis 2009; 19(2): 110-4.
219. Gaborit B, Jacquier A, Kober F, et al. Effects of Bariatric Surgery on Cardiac Ectopic Fat: Lesser Decrease in Epicardial Fat Compared to Visceral Fat Loss and No Change in Myocardial Triglyceride Content. J Am Coll Cardiol 2012; 60(15): 1381-9.
220. Vest AR, Heneghan HM, Agarwal S, et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 2012.
221. Ikonomidis I, Mazarakis A, Papadopoulos C, et al. Weight loss after bariatric surgery improves aortic elastic properties and left ventricular function in individuals with morbid obesity: a 3-year follow-up study. J Hypertens 2007; 25(2): 439-47.
222. Maser RE, Lenhard MJ, Peters MB, et al. Effects of surgically induced weight loss by Roux-en-Y gastric bypass on cardiovascular autonomic nerve function. Surg Obes Relat Dis 2011.
223. Bobbioni-Harsch E, Sztajzel J, Barthassat V, et al. Independent evolution of heart autonomic function and insulin sensitivity during weight loss. Obesity (Silver Spring) 2009; 17(2): 247-53.
224. Nerla R, Tarzia P, Sestito A, et al. Effect of bariatric surgery on peripheral flow-mediated dilation and coronary microvascular function. Nutr Metab Cardiovasc Dis 2012; 22(8): 626-34.
225. Patle R, Dubb S, aghband-Zadeh J, et al. Improved blood pressure, nitric oxide and asymmetric dimethylarginine are independent after bariatric surgery. Ann Clin Biochem 2012.
226. Sledzinski T, Sledzinski M, Smolenski RT, et al. Increased serum nitric oxide concentration after bariatric surgery--a potential mechanism for cardiovascular benefit. Obes Surg 2010; 20(2): 204-10.
227. Rakhit RD, Marber MS. Nitric oxide: an emerging role in cardioprotection? Heart 2001; 86(4): 368-72.
228. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271(5 Pt 1): C1424-37.
229. Ashrafian H, le Roux CW, Darzi A, et al. Effects of bariatric surgery on cardiovascular function. Circulation 2008; 118(20): 2091-102.
230. Ueda Y, Hajri T, Peng D, et al. Reduction of 8-iso-prostaglandin F2alpha in the first week after Roux-en-Y gastric bypass surgery. Obesity (Silver Spring) 2011; 19(8): 1663-8.
231. Vazquez LA, Pazos F, Berrazueta JR, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 2005; 90(1): 316-22.
232. Habib P, Scrocco JD, Terek M, et al. Effects of bariatric surgery on inflammatory, functional and structural markers of coronary atherosclerosis. Am J Cardiol 2009; 104(9): 1251-5.
233. Graziani F, Biasucci LM, Cialdella P, et al. Thromboxane production in morbidly obese subjects. Am J Cardiol 2011; 107(11): 1656-61.
234. de Andrade AR, Cotrim HP, Alves E, et al. Nonalcoholic fatty liver disease in severely obese individuals: the influence of bariatric surgery. Ann Hepatol 2008; 7(4): 364-8.
235. Rabl C, Campos GM. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis 2012; 32(1): 80-91.
236. Ghanim H, Monte SV, Sia CL, et al. Reduction in inflammation and the expression of amyloid precursor protein and other proteins related to Alzheimer's disease following gastric bypass surgery. J Clin Endocrinol Metab 2012; 97(7): E1197-201.
237. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292(14): 1724-37.